# SCRIMED p.34 Implementation Status

Status: local clinical operating-system, workflow, model-fit, action-maturity, continuity, and evidence controls are implemented and validated; exact-candidate named review remains pending.

The integrated p.34 control plane now includes versioned workflow contracts, documentary provider capability evidence, deterministic-first model-fit routing, an append-only action-maturity chain, evidence-gated pilot expansion, non-PHI continuity measures, public-sector evidence profiles, isolated challenger evaluations, privacy-safe workflow ROI telemetry, review-only A0-A3 approval evaluation, tenant-scoped clinical governance evidence, PHI/secret egress policy, sandbox policy review, authenticated tenant-first retrieval, external-validation and oversight gates, Patient Take-Home previews, assisted coding boundaries, bounded recovery, and evidence-bound claim review. These extend the existing p.33/p.34 authorization and governance controls; they do not create a second execution framework.

No dependency, database migration, provider call, production mutation, PHI operation, clinical action, EHR/payer/system-of-record write, challenger activation, public-sector claim, deployment, customer activation, or external distribution is part of this candidate.

## Verified Local Evidence

- Node `v24.19.0` direct quality runner: 10/10 gates passed on the final pre-commit tree.
- Existing p.34 policy tests: 40/40 passed.
- Workflow, model-fit, action, and continuity policy tests: 27/27 passed.
- Clinical operating-system policy tests: 42/42 passed.
- p.34 contract checks: 67/67 existing and 66/66 clinical operating-system assertions passed.
- Deterministic p.34 artifact integrity: 2/2 artifacts passed; validation report 31/31 checks.
- Full nonsecret suite: passed, including 277 registered package scripts and 10 CI workflow contracts.
- TypeScript typecheck, full ESLint, Next.js `16.2.12` production build, built public-release verification, and generated integrity: passed.
- Built route verification: 628 routes; `/scrimed-p34` and the p.34 catch-all API included.
- Browser verification: default desktop, explicit 1440x900, and 390x844; no horizontal overflow, error overlay, console warning, or console error.
- Eleven new read-only clinical-OS endpoints returned HTTP 200 from the compiled production route. Seven unauthenticated mutation attempts failed closed with typed `503` responses.
- Secret scan: 1,739 files, 0 findings.
- SBOM: 422 components with no direct or transitive dependency delta; the exact fingerprint is generated after the local candidate commit to avoid self-referential evidence.
- Pending-migration static packet: three migrations, checksum ordering passed, fingerprint `0d6ae59a759758cd`; no disposable dry run or migration was executed.
- `git diff --check`: passed.

## p.34 Gate Matrix

- `PASS`: 21 local, deterministic controls.
- `OPERATOR_REQUIRED`: 2 gates: exact-candidate independent review and named pilot-expansion approvals.
- `BLOCKED`: 5 gates: PHI/clinical authority, production/customer authority, public-sector documentary claims, challenger promotion, and external clinical validation.
- `FAIL`: 0.

Passing a local control confirms the synthetic implementation behavior only. It does not authorize external execution or satisfy a blocked/operator gate.

## Retained External State

External GitHub, Vercel, Supabase, model-provider, public-sector, and customer systems were not queried or changed during this upgrade. Earlier external evidence is not promoted to this candidate automatically. The existing leaked-password-protection warning, three unapplied migrations, AAL2 evidence requirements, reviewer separation, and deployment/customer controls remain retained operator gates until refreshed against the exact candidate.

The build completed through the supported Next.js webpack path. The only build warning observed was the absence of a configured build cache; the historical native-SWC warning did not recur in this run and is not claimed resolved across other environments.

## Readiness Boundaries

- Internal synthetic/no-PHI demonstration: locally validated; exact-candidate named review required before evidence promotion.
- External non-PHI pilot or cohort expansion: named operational, privacy/security, clinical-when-applicable, customer, and release authorization required.
- PHI-capable, clinical, payer, EHR, device, or external-provider path: blocked.
- Public-sector compliance, authorization, or purchasing-eligibility claim: blocked pending documentary evidence and named review.
- Challenger production registration or promotion: blocked pending reproducible local evidence, licensing/infrastructure review, and named approval.
- Production release, migration, external distribution, or customer activation: blocked.
